SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Politics : High Tolerance Plasticity -- Ignore unavailable to you. Want to Upgrade?


To: JHP who wrote (13278)4/15/2002 8:45:42 AM
From: Think4Yourself  Respond to of 23153
 
That's great news about ENMD and hopefully you will get a big trading bounce from it.

These are "pre-clinical" findings. Not sure what that means. Do they have the funds to get it through trials, and do they have the funds to still be in business when trials are over? Are the licensing rights worth anything before the drug is approved by the FDA? What do companies typically do if they DON'T have the funds to get a promising drug through trials?

Not meaning to be negative. Really don't know the answers to these questions. Would appreciate any enlightenment folks willing to provide on how the industry works in general. Still trying to learn this industry and how it works. Nowhere near as straightforward as oil and gas was. Also don't know folks as knowledgeable and willing to share info as the oil/gas folks who were on the original Strictly Drilling thread. THAT was a great source on information before it degenerated.



To: JHP who wrote (13278)4/15/2002 10:42:21 AM
From: LLCF  Read Replies (1) | Respond to of 23153
 
<<EntreMed's Thalidomide Analog Powerful Against Multiple Myeloma in Preclinical Studies >>

Interesting... doesn't CELG own Thalidomde now and ENMD recieves potential royalties??? Perhaps CELG is a buy also? "Preclinical" may reduce enthusiasm in this market. 5 years to market?

DAK